U.S. Hospitality Stock News

OTCPK:FNMA
OTCPK:FNMADiversified Financial

A Look At Fannie Mae (OTCPK:FNMA) Valuation As Crypto Backed Mortgages Draw Fresh Market Attention

Federal National Mortgage Association (FNMA) has drawn fresh scrutiny after announcing plans to accept crypto backed mortgages. The move directly links Bitcoin funded home loans with its traditional residential finance platform and raises new questions about risk, collateral quality, and investor perception. See our latest analysis for Federal National Mortgage Association. The announcement lands at a time when momentum around Federal National Mortgage Association has been mixed, with a sharp...
NYSE:MDT
NYSE:MDTMedical Equipment

Medtronic And GE HealthCare Tie Imaging Push To Neurosurgery Growth Potential

Medtronic (NYSE:MDT) and GE HealthCare have launched an integrated, real-time cranial surgical imaging platform that connects Stealth AXiS navigation with bkActiv intraoperative ultrasound. The system combines live ultrasound with pre-operative MRI and CT data, supported by AI tools, to support neurosurgeons during complex cranial procedures. The platform is scheduled to debut at the 2026 AANS Scientific Meeting, with features including specialized algorithms, color Doppler, remote controls,...
NYSE:AKR
NYSE:AKRRetail REITs

Is It Too Late To Consider Acadia Realty Trust (AKR) After Its Recent Share Price Rebound?

Investors may be wondering whether Acadia Realty Trust is offering good value at its current price, or if the easier gains have already passed. The stock recently closed at US$20.37, with returns of 4.9% over the last week, a 1.6% decline over the last month, a 1.3% decline year to date, 14.3% over the last year, 74.9% over three years, and 23.6% over five years. Recent coverage has focused on Acadia as a retail focused REIT, with ongoing attention on how its portfolio and tenant mix...
NYSE:CRGY
NYSE:CRGYOil and Gas

Is It Time To Reassess Crescent Energy (CRGY) After Its 78.8% One Year Surge?

If you are wondering whether Crescent Energy's current share price reflects its true worth, the recent trading pattern gives you plenty to think about. The stock has seen a 48.6% return year to date and 78.8% over the last year, with a recent 6.9% 30 day move and a 5.9% pullback over the past week that may have shifted how the market views its risk and reward trade off. Recent news coverage has focused on Crescent Energy's position in the US energy sector and how investors are reacting to...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Biogen and Alloy Therapeutics have entered a new collaboration to develop multi target antisense oligonucleotide drugs using Alloy’s AntiClastic ASO platform. The partnership focuses on several undisclosed genetic disease targets and marks Biogen’s first announced use of an advanced antisense platform across multiple programs. For investors watching NasdaqGS:BIIB at a share price of $177.11, this move adds a fresh angle to the story. The stock shows mixed medium to long term performance,...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

Is It Time To Revisit Zscaler (ZS) After Its Recent Share Price Slide

If you are wondering whether Zscaler's current share price lines up with its underlying worth, this article will walk through what the numbers actually suggest about value. The stock recently closed at US$122.23, with returns of 11.8% decline over 7 days, 20.5% decline over 30 days, 44.6% decline year to date, 38.3% decline over 1 year, 15.9% gain over 3 years and 36.5% decline over 5 years. Taken together, these figures give you a mixed picture of past performance. Recent headlines around...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead’s Deal Spree Shifts Pipeline Toward Oncology And Potential Upside

Early 2026, Gilead Sciences (NasdaqGS:GILD) has moved quickly on acquisitions of Arcellx, Ouro Medicines, and Tubulis. The company has also exercised exclusive licensing options with Cartography Biosciences for solid tumor targets and Kymera Therapeutics for a CDK2 molecular glue degrader. These deals expand Gilead's oncology and autoimmune pipelines and reduce reliance on its established HIV and legacy franchises. Gilead Sciences, trading at around $142.09, is drawing fresh attention as...
NYSE:HII
NYSE:HIIAerospace & Defense

Is It Too Late To Consider Huntington Ingalls Industries (HII) After 104% One Year Return?

If you are wondering whether Huntington Ingalls Industries at around US$403 per share still offers value, the starting point is understanding what the current price actually reflects. The stock has posted a 15.3% return year to date, with a 1.7% move over the last week, a 3.4% decline over the last month, and returns of 104.5% over 1 year, 103.5% over 3 years, and 116.1% over 5 years. These moves have kept Huntington Ingalls Industries on the radar for investors tracking Aerospace & Defense...
NasdaqCM:TH
NasdaqCM:THHospitality

Assessing Target Hospitality (TH) Valuation After Major Hyperscaler Data Center Contract And 2026 Guidance Raise

Target Hospitality (TH) is back in focus after securing a multi year contract with a top five hyperscaler for a North Texas data center campus and raising its 2026 earnings guidance in response. See our latest analysis for Target Hospitality. The recent contract win and 2026 guidance update have coincided with sharp price momentum, with a 30 day share price return of 86.72% and a year to date gain of 83.95%, while the 1 year total shareholder return of 121.73% suggests this latest move builds...
NYSE:WES
NYSE:WESOil and Gas

Is Western Midstream Partners (WES) Still Attractive After Strong 5 Year Price Performance

If you are wondering whether Western Midstream Partners at around US$40.94 is still offering value, you are not alone. This article focuses on exactly that question. The unit price has moved by 2.1% over the last 30 days, with a 25.2% return over 1 year and a very large 217.2% return over 5 years. This naturally raises questions about how much value is already reflected in the current price. Recent news coverage has mainly centered on Western Midstream Partners as a key player in the US...
NYSE:AES
NYSE:AESRenewable Energy

Is AES (AES) Offering Value After A 48% One Year Share Price Rebound?

Investors may be wondering whether AES at around US$14.41 is offering fair value or a potential mispricing opportunity, especially after its recent share price swings. AES has returned 0.8% over the last week, 1.4% over the last month and 47.9% over the last year, set against a year to date decline of 2.8% and multi year declines of 35.3% over three years and 39.0% over five years. Recent coverage has focused on how utility and power related names like AES are being reassessed as investors...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Assessing Affirm Holdings (AFRM) Valuation After Recent Share Price Volatility

Recent performance snapshot With no single headline event driving Affirm Holdings (AFRM) today, the focus turns to how the stock has traded recently and what its current fundamentals might mean for your expectations and risk tolerance. The share price closed at US$49.01, with a 1.6% decline over the past day, a 5.8% gain over the past week, a 1.5% decline over the past month, and a 40.1% decline over the past 3 months. See our latest analysis for Affirm Holdings. For context, Affirm’s recent...
NYSE:ICE
NYSE:ICECapital Markets

Is It Too Late To Consider Intercontinental Exchange (ICE) After Recent Share Price Strength?

Wondering if Intercontinental Exchange at around US$161.97 is still a fair entry point or if the value story has already played out? This article focuses squarely on what the current price might imply. The stock has moved by 1.1% over the last 30 days and 5.6% over the past year, with a 56.5% return over 3 years and 44.1% over 5 years, which hints at a long track record that many investors will be weighing against today's valuation. Recent coverage has focused on Intercontinental Exchange as...
NYSE:PACS
NYSE:PACSHealthcare

Is It Too Late To Consider PACS Group (PACS) After Its 1-Year Surge?

Investors may be wondering whether PACS Group at around US$35.97 is still offering value after its strong run, or if the easy gains are already behind it. The stock has moved 11.9% over the last 7 days and 5.3% over the last 30 days, while the 1 year return of 286.8% contrasts with a year to date return of a 9.0% decline. Recent attention on PACS Group has centered on its strong 1 year share price performance and the healthcare services segment it operates in. This has made the stock more...
NYSE:F
NYSE:FAuto

Is Ford (F) Quietly Recasting Its Manufacturing Edge With the Sharrow Propeller Partnership?

In early April 2026, Sharrow Engineering announced it is scaling production of its patented Sharrow Propeller with Ford’s Advanced Industrial Technology & Platforms team, using 3D sand-casting to cut manufacturing timelines from around 130 days to roughly two weeks while preserving the precision needed for high-performance marine and mobility applications. This collaboration not only helps Sharrow meet growing demand but also showcases how Ford is applying its advanced manufacturing...
NYSE:GEV
NYSE:GEVElectrical

GE Vernova’s AFRY SMR Deal Expands Nuclear Story In Europe

GE Vernova Hitachi Nuclear Energy has signed a Main Services Agreement with AFRY to support the rollout of its BWRX-300 small modular reactor technology across Europe. The agreement targets faster deployment of SMRs and development of a local industrial ecosystem around the BWRX-300 platform. This marks a material expansion of GE Vernova's international nuclear efforts beyond its current focus in the U.S. and Canada. For investors tracking NYSE:GEV, this new agreement arrives with the...
NasdaqGS:EBAY
NasdaqGS:EBAYMultiline Retail

eBay’s SAIL Role Puts AI Patent Access In Investor Focus

eBay has joined the newly launched Shared AI License Foundation as a founding board observer. The foundation brings together companies such as Anthropic, IBM, Meta, and Microsoft to share access to foundational AI patents. The initiative aims to support faster AI development through a shared patent framework. For investors watching NasdaqGS:EBAY, this move ties directly into how the company may use AI to refine its marketplace and improve user experience. The stock trades at $95.58, with...
NasdaqGS:TTEK
NasdaqGS:TTEKCommercial Services

Is It Time To Reassess Tetra Tech (TTEK) After Recent Share Price Weakness

If you are wondering whether Tetra Tech's current share price offers good value or if you might be overpaying for quality, this article walks through the key valuation checks that matter most. The stock last closed at US$30.85, with a 0.7% decline over 7 days, an 8.1% decline over 30 days, and an 8.3% decline year to date. The 1 year, 3 year, and 5 year returns sit at 6.2%, 7.2%, and 16.9% respectively. Recent price movements are occurring against a backdrop of ongoing investor interest in...
NYSE:COR
NYSE:CORHealthcare

Assessing Cencora (COR) Valuation After Recent Share Price Weakness

Cencora stock reaction and recent performance Cencora (COR) has recently drawn investor attention after a period of weaker share performance, with the stock down about 8% over the past month and roughly 4% over the past 3 months. At a last close of US$322.46 and a market value of about US$63.2b, the company pairs large scale distribution operations with continued revenue and net income growth on an annual basis. See our latest analysis for Cencora. While the recent 30 day share price return...
NasdaqGS:GSAT
NasdaqGS:GSATTelecom

Assessing Globalstar (GSAT) Valuation After A Year Of Strong Returns And Ongoing Apple Partnership Hopes

How Globalstar’s Recent Performance Frames the Investment Question Globalstar (GSAT) has drawn fresh attention after a period where its share price moved about 24% over the past month and about 22% over the past 3 months, prompting investors to reassess the satellite operator. See our latest analysis for Globalstar. That recent 24.4% 1 month share price return and 21.9% 3 month share price return sit alongside a 278.9% 1 year total shareholder return, suggesting momentum has been strong, even...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Assessing Duolingo (DUOL) Valuation After Revenue Beat AI Investment Push And Legal Scrutiny

Duolingo (DUOL) is drawing attention after reporting strong revenue growth that exceeded analyst expectations, while signaling a focus on user growth over near term profitability, and facing legal scrutiny following investor losses. See our latest analysis for Duolingo. The recent focus on user growth, heavier AI investment and the legal investigation has coincided with a 48.7% year to date share price return decline and a 71.44% 1 year total shareholder return decline. This suggests that...
NasdaqCM:PROP
NasdaqCM:PROPOil and Gas

Prairie Operating (PROP) Is Down 42.7% After Swinging to Profit and Issuing 2026 Guidance - What's Changed

Prairie Operating Co. reported past full-year 2025 results on March 30, 2026, showing revenue of US$241.65 million versus US$7.94 million a year earlier and moving from a net loss of US$40.91 million to net income of US$32.05 million, alongside detailed production disclosure. Management also issued production and earnings guidance for 2026, targeting average daily output of 25,500–27,500 Boe/d and net income of US$55 million to US$65 million, highlighting how operational scale now ties...
NYSE:TXT
NYSE:TXTAerospace & Defense

Will New Special-Mission Deals and Upgraded SkyCourier Capabilities Change Textron's (TXT) Narrative?

Over the past week, Textron Aviation secured fresh defense and special-mission business with Belgium and the Peruvian Army, while also unveiling an in‑flight operable door for the Cessna SkyCourier that expands its military, humanitarian and commercial mission roles from around 2028. This combination of new international government customers and mission‑enhancing product features underlines how Textron is deepening its role in specialized defense and relief aviation. We’ll now examine how...
NYSE:INSP
NYSE:INSPMedical Equipment

Has Inspire Medical Systems (INSP) Fallen Too Far After A 60.8% One-Year Slide?

Wondering if Inspire Medical Systems at around US$56.69 is a bargain or a value trap? This article focuses on what the current price really implies about the stock. The share price has seen mixed recent moves, with a 3.1% gain over the last 7 days, a 4.6% decline over 30 days, and year to date and 1 year returns of 38.6% and 60.8% declines respectively. Recent coverage has focused on how the share price performance over multiple time frames compares to broader market and industry moves,...